VB19055
Phase 1Small molecule
VB19055 is one of 33 small molecule programs targeting Hypertension. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
157 competitors in Hypertension
#DrugCompanyPhaseTrials
1Foundayo
Eli LillyPhase 3
Alka-Seltzer
AAbbott
Phase 3
Minocycline /d
UUniversity of Florida
Phase 3
HCP1803-3
Hanmi Pharmaceutical Company LimitedPhase 3
SGLT2
PProf. Dr. med. Ingo Eitel
Phase 3
Avastin
RochePreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VB19055. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details